Elektra Health Review: Clinical Gaps, Limitations, and What to Know Before You Sign Up

What Is Elektra Health and Is It Legitimate?

Elektra Health is a real, operating telehealth service staffed by licensed clinicians. It is not a supplement brand or a wellness-only site. Its focus is menopause education paired with clinical care, and it prescribes hormone therapy and certain non-hormonal medications through asynchronous and synchronous telehealth visits.

Legitimacy, though, is not the same as being the right fit for every woman. The platform is genuine. Whether its clinical depth matches your specific situation is a different question, and that is what this review addresses.

The Origin Problem in Menopause Care

Menopause has been chronically underfunded and understudied. Only about 20 percent of U.S. Medical residency programs include any formal menopause training, which helps explain why platforms like Elektra Health exist at all: they fill a gap the traditional healthcare system largely created. That context matters when you evaluate any menopause telehealth company. The bar in primary care is low. The question is whether a specialized platform clears a meaningfully higher one.

Staffing and Credentials

Elektra employs physicians and nurse practitioners with stated menopause training. The Menopause Society (formerly NAMS) Certified Menopause Practitioner (NCMP) credential is the recognized standard in the U.S. When evaluating any telehealth menopause service, you should ask specifically whether your assigned clinician holds this credential, not just whether the platform "specializes in menopause." Elektra does not publicly list NCMP status for all practitioners on its site.

What Elektra Health Does Well

The platform's strongest contribution is menopause education delivered in an accessible, women-centered format. Its content library and group coaching model address a real gap.

Education and Community Model

Most clinical visits for menopause last under 15 minutes. Elektra's group education sessions are a meaningful supplement, covering symptom tracking, lifestyle strategies, and what to expect from hormone therapy. Women who enter perimenopause without context often leave clinical visits more confused than when they arrived. Group education helps.

Peer community also has documented benefit. A 2023 Menopause journal analysis found that social support was independently associated with reduced menopause-related distress, which gives the community model a real evidence basis, not just a marketing rationale.

Prescribing for Common Presentations

For a woman with straightforward vasomotor symptoms, no significant cardiovascular or thrombotic history, and no active hormone-sensitive malignancy history, Elektra can prescribe menopausal hormone therapy (MHT), including FDA-approved estradiol and progesterone formulations. It also offers vaginal estrogen for genitourinary syndrome of menopause (GSM), which is underused and under-prescribed despite strong safety data. That is a genuine clinical contribution.

Where the Clinical Gaps Are

This is the section most competitor reviews skip. Elektra performs reasonably for uncomplicated presentations. The gaps become apparent when a woman's history is more complex.

Gap 1: No Physical Examination Capability

Every telehealth platform shares this limitation, but it matters more in menopause care than some other conditions. Pelvic floor assessment, breast exam, and blood pressure measurement (relevant when prescribing combined estrogen-progestogen) cannot be done remotely. ACOG guidance on menopause management expects baseline cardiovascular risk assessment before initiating systemic MHT. Elektra relies on self-reported history and any labs a woman uploads or orders through a partner lab, which is a workable but structurally limited model.

Gap 2: Limited Scope for High-Risk or Complex Presentations

Women with the following histories require more intensive clinical oversight than a telehealth education platform typically provides:

• Personal or first-degree family history of estrogen-receptor-positive breast cancer
• History of venous thromboembolism or factor V Leiden
• Cardiovascular disease or a Framingham 10-year risk score above 10 percent
• Active or recent endometrial pathology
• Severe or treatment-resistant depression coinciding with perimenopause

The Menopause Society's 2023 position statement is explicit: individualized risk stratification must precede hormone therapy initiation. Telehealth platforms can conduct portions of this assessment, but they cannot replicate the iterative, exam-informed process that a complex case requires.

Gap 3: The Perimenopause-to-Reproductive-Years Transition

Perimenopause can begin in the late 30s. The menopausal transition typically spans 4 to 8 years, meaning many women are symptomatic while still having irregular cycles, active fertility concerns, or overlapping PCOS. Elektra's model is oriented toward postmenopause or well-established perimenopause. A woman in her early 40s with PCOS, irregular cycles, and vasomotor symptoms does not fit neatly into the platform's core workflow.

This is a structural gap that most menopause telehealth platforms share, and it deserves naming. We call it the perimenopausal overlap problem: the women who are hardest to categorize hormonally are often the women least well served by condition-specific platforms. If you are 38 to 44, still having periods (however erratically), and experiencing symptoms that could be PCOS, perimenopause, or both, you likely need a clinician trained in reproductive endocrinology or OB-GYN generalism, not a menopause specialist platform alone.

Gap 4: Monitoring Protocols After Initiation

Starting hormone therapy is one clinical decision. Managing it over time, including endometrial protection assessment for women on estrogen-only therapy, annual cardiovascular check-ins, and bone density monitoring per USPSTF osteoporosis screening guidance, requires ongoing clinical infrastructure. Telehealth platforms vary considerably in how well they support this longitudinal phase. Ask any menopause telehealth provider directly: what is the protocol for monitoring endometrial safety in a woman prescribed unopposed estrogen? The answer is informative.

Gap 5: Mental Health Integration

Perimenopause is associated with a two-to-four-fold increase in risk for major depressive episode compared to premenopausal years. This is not a mood problem adjacent to menopause. It is a neurobiological consequence of fluctuating estradiol acting on serotonin and norepinephrine systems. Adequate menopause care should include screening for depression and either integrated mental health support or a clear referral pathway. Elektra's platform does not offer integrated behavioral health as a clinical service.

Hormone Therapy: What Elektra Can and Cannot Prescribe

Elektra prescribes FDA-approved MHT formulations. Understanding what that includes, and what it excludes, helps you evaluate fit.

What Is Available

• Oral and transdermal estradiol (patches, gels, sprays)
• Micronized progesterone (Prometrium) for uterine protection in women with a uterus
• Vaginal estrogen (cream, ring, tablet) for GSM
• Some non-hormonal options, including SSRIs/SNRIs for vasomotor symptoms

What Is Less Clear

Compounded bioidentical hormone therapy (CBHT) is controversial. The Menopause Society explicitly does not recommend compounded hormones as a first-line option because they lack FDA approval for safety, efficacy, and dosing consistency. Whether Elektra prescribes CBHT or steers toward FDA-approved options is worth asking directly. The clinical evidence favors FDA-approved formulations.

Testosterone for hypoactive sexual desire disorder (HSDD) in postmenopausal women is a real clinical need. A 2019 Lancet Diabetes and Endocrinology systematic review found testosterone improved sexual function in postmenopausal women. No FDA-approved testosterone product is labeled for women in the U.S., so off-label prescribing or compounding is required. Whether Elektra has a protocol for this is unclear from public information, and it is a gap for women seeking comprehensive sexual health care.

Pregnancy, Lactation, and Contraception: What You Must Know

This section applies to women who are perimenopausal but still potentially fertile, which is more common than most women realize.

Perimenopause does not equal infertility. Ovulation can occur unpredictably during the menopausal transition even when cycles are very irregular. ACOG advises that contraception should be used until 12 consecutive months of amenorrhea in women under 50, and until 24 months in women under 45, because unintended pregnancy during perimenopause carries elevated maternal and fetal risk.

Systemic MHT is not contraception. A woman who is prescribed MHT through any telehealth platform and who has not yet reached confirmed menopause needs a concurrent contraceptive plan. Elektra's platform, based on publicly available information, does not appear to offer contraceptive prescribing as a core service. You may need a separate provider for this.

Hormone therapy and pregnancy: Systemic estrogen-progestogen therapy is contraindicated in pregnancy. If you are perimenopausal and using MHT, a positive pregnancy test requires immediate contact with an OB-GYN.

Lactation: Menopause and lactation do not typically co-occur in clinical practice, but postpartum women can have estrogen-deficiency symptoms that resemble perimenopause. Lactation suppresses estradiol via elevated prolactin, causing vaginal dryness, hot flashes, and mood changes. Low-dose vaginal estrogen is generally considered compatible with breastfeeding in clinical practice, though LactMed data on vaginal estrogen remain limited. Elektra does not serve postpartum women as a stated population.

Elektra Health Cost and Insurance

Elektra accepts some commercial insurance plans. Cash-pay pricing for clinical visits varies. The education and coaching programs are typically a separate subscription cost. This two-part pricing model means you may pay for both a clinical consultation and a membership to access educational content, which is worth factoring into total cost of care.

For context: a single visit with a menopause-certified OB-GYN in a traditional practice may cost $150 to $350 out of pocket. Telehealth menopause platforms often price initial visits similarly, with follow-up structures varying considerably.

Ask before signing up:

• Does my insurance cover clinical visits specifically, or only the education component?
• Is there a separate subscription fee, and what happens to my prescriptions if I cancel?
• What is the follow-up visit cadence, and what does each visit cost?

Who Elektra Health Is and Is Not Right For

Right for you if:

• You are in confirmed perimenopause or postmenopause with typical vasomotor symptoms
• You have no significant cardiovascular, thrombotic, or hormone-sensitive cancer history
• You want structured menopause education and peer community alongside clinical care
• You are already working with a primary care physician who can handle physical exams and ongoing monitoring
• You live in a state where menopause-trained telehealth prescribers are scarce in person

Likely not sufficient as your only provider if:

• You are 38 to 44 with irregular cycles and overlapping PCOS or thyroid issues
• You have a personal history of breast cancer, DVT, pulmonary embolism, or active cardiovascular disease
• You need contraception alongside any hormonal treatment
• You require integrated mental health care for perimenopausal depression or anxiety
• You are postpartum and experiencing estrogen-deficiency symptoms during lactation
• You need testosterone therapy for HSDD with clear monitoring

Elektra Health vs. Alternatives: A Direct Comparison

Several telehealth platforms now serve the menopause space. The field differs by prescribing depth, clinician credentialing, and whether clinical care is separated from education.

Midi Health offers synchronous telehealth visits with prescribers and has stated NCMP-credentialed clinicians on staff, with broader reproductive-years integration than Elektra.

Gennev (now partnered with Unified Women's Healthcare) similarly combines clinical prescribing with community features.

Alloy Women's Health is prescription-focused with a streamlined questionnaire model, lower on education but faster on initiation.

Direct primary care (DPC) or OB-GYN with NCMP credential remains the gold standard for complex presentations. The Menopause Society's provider finder allows you to search for NCMP-credentialed clinicians by zip code, and many now offer telehealth.

The honest comparison: Elektra's differentiation is education quality and community. If you are primarily looking for a prescriber, other platforms may be more efficient. If you want context and community alongside a prescription, Elektra's model has genuine value.

Evidence Gaps and What Is Extrapolated

Women have been consistently under-represented in cardiovascular and metabolic trials, and menopause research has historically lagged behind general medicine. Several claims common in menopause telehealth marketing deserve scrutiny:

"Bioidentical hormones are safer than conventional HRT." This claim is not supported by direct trial evidence. The Menopause Society's 2020 compounded hormone therapy position statement states there is no evidence that compounded hormones are safer or more effective than FDA-approved options, and they carry additional risks of dosing inconsistency.

"Hormone therapy after 60 is too risky." The Menopause Society's 2023 hormone therapy position statement explicitly states: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms." The blanket age cutoff is not evidence-based.

Bone protection claims. MHT does reduce fracture risk, but the degree of benefit depends on formulation, dose, and duration, none of which are identical across telehealth prescribers. Any platform that implies hormone therapy fully substitutes for bone density monitoring is overstating the evidence.

A Clinician's Perspective on What to Ask Any Menopause Telehealth Provider

The following questions come from our editorial board reviewer, Elena Vasquez, MD, OB-GYN:

"Before you book with any menopause telehealth platform, ask three things: Does my prescriber hold an NCMP credential or equivalent training? What is your protocol for endometrial monitoring in women on estrogen-only therapy? And, if my symptoms do not improve in 12 weeks, what happens next? If you get vague answers to any of those, look elsewhere. Menopause care is not simple, and a platform that makes it sound simple is cutting corners somewhere."

These are not trick questions. A well-staffed menopause service should answer all three without hesitation.

FAQs